Bridgewater Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.47M Sell
3,983
-68
-2% -$69.5K 0.24% 54
2026
Q1
$4.12M Buy
4,051
+110
+3% +$112K 0.24% 55
2025
Q4
$4.25M Sell
3,941
-14
-0.4% -$13.4K 0.28% 52
2025
Q3
$3.71M Buy
3,955
+11
+0.3% +$8.19K 0.26% 57
2025
Q2
$3.01M Buy
3,944
+39
+1% +$30.3K 0.23% 59
2025
Q1
$3.46M Buy
+3,905
New +$3.25M 0.3% 49
2022
Q3
Sell
-828
Closed -$268K 180
2022
Q2
$268K Sell
828
-52
-6% -$15.6K 0.06% 195
2022
Q1
$252K Buy
880
+57
+7% +$14.7K 0.06% 208
2021
Q4
$227K Buy
+823
New +$209K 0.05% 226

Other funds holding LLY

Bridgewater Advisors's LLY Position: Q2 2026 in Review

Bridgewater Advisors reduced its Eli Lilly (LLY) stake by 1.7% in Q2 2026, selling an estimated $69.5K and leaving 3,983 shares worth $4.47M. The position accounts for 0.24% of the portfolio, ranked #54.

Bridgewater Advisors first reported a position in LLY in Q4 2021 and has held it in 9 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Bridgewater Advisors held 3,983 shares of Eli Lilly worth $4.47M as of Q2 2026.
  • Bridgewater Advisors sold 68 Eli Lilly shares in Q2 2026, an estimated $69.5K.
  • Eli Lilly made up 0.24% of Bridgewater Advisors's portfolio in Q2 2026, its #54 holding.
  • Bridgewater Advisors first reported a position in Eli Lilly in Q4 2021 and has held it in 9 quarters since.
  • 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Bridgewater Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.